

Review Article

Open Access

Comorbidities of HIV/AIDS and the Role of Artificial Intelligence in Treatment, Prevention, and Education

Uchechukwu Promise Ahanonu^{1*}, Feyisara Lawal Abati²

¹MPH Public Health Researcher Chicago, Illinois, United States.

²MPH Environmental Health Specialist Peoria, Illinois, United States.

*Corresponding author: Uchechukwu Promise Ahanonu.

Abstract

The HIV/AIDS epidemic continues to affect millions globally, even in the face of remarkable progress in antiretroviral therapy (ART). While ART has significantly improved the life expectancy of people living with HIV (PLWH), the chronic nature of the disease and long-term medication use have led to a growing burden of comorbidities such as cardiovascular disease, cancer, neurocognitive disorders, metabolic complications, and osteoporosis. These comorbidities necessitate more holistic and tailored healthcare strategies. In parallel, artificial intelligence (AI) is revolutionizing the healthcare landscape by offering predictive, personalized, and scalable solutions in disease management. This paper explores the biological and clinical basis of HIV/AIDS-related comorbidities and evaluates the transformative potential of AI in improving treatment adherence, enhancing prevention strategies, and personalizing educational tools. Integrating AI into HIV/AIDS management can significantly enhance outcomes, particularly in resource-limited settings, and offers a glimpse into the future of precision public health.

Keywords: although antiretroviral therapy; artificial intelligence; neurocognitive disorders

Introduction

HIV/AIDS has remained a persistent and complex global public health concern. Although antiretroviral therapy (ART) has revolutionized the care landscape—turning HIV from a fatal disease into a manageable chronic condition—comorbidities now represent a major challenge in the long-term health of people living with HIV (PLWH). These conditions include cardiovascular diseases, certain cancers, neurocognitive disorders, metabolic abnormalities, and bone-related complications, all of which significantly affect quality of life and care complexity. Emerging digital technologies, particularly artificial intelligence (AI), are offering new tools to support and streamline HIV care. AI applications in healthcare include machine learning (ML), natural language processing (NLP), and data analytics. These innovations are being utilized to optimize treatment, improve prevention outreach, and customize patient and provider education. This paper outlines the interplay between HIV/AIDS comorbidities and AI's role in managing and transforming HIV healthcare delivery.

Comorbidities of HIV/AIDS

Cardiovascular Diseases (CVD)

People living with HIV are at heightened risk for cardiovascular diseases such as hypertension, myocardial infarction, and stroke. This is due to a complex interplay of chronic immune activation, inflammation, ART-induced lipid abnormalities, and lifestyle factors. Studies show that PLWH have a 50–100% increased risk of cardiovascular events compared to individuals without HIV (Triant, 2013).

Cancers

The risk of developing certain cancers is elevated in PLWH due to HIV-induced immunosuppression. AIDS-defining cancers include Kaposi's sarcoma, non-Hodgkin lymphoma, and cervical cancer. Additionally, non-AIDS-defining malignancies such as anal, lung, and liver cancer are more common in this population. Oncogenic viruses, like human papillomavirus (HPV) and Epstein-Barr virus (EBV), tend to have greater oncogenic potential in immunocompromised hosts (Shiels et al., 2011).

Neurocognitive Disorders

HIV-associated neurocognitive disorders (HAND) remain prevalent, despite viral suppression with ART. HAND includes a range from mild cognitive impairment to more severe dementia. These disorders are believed to stem from direct viral effects on the brain and ongoing neuroinflammation. Cognitive dysfunction can impair memory, attention, and

executive function, leading to decreased adherence and poorer overall outcomes (Heaton et al., 2010).

Metabolic Disorders

ART, particularly regimens that include protease inhibitors, can lead to metabolic complications such as insulin resistance, lipodystrophy, and dyslipidemia. These issues elevate the risk of developing type 2 diabetes and metabolic syndrome. Lifestyle factors, aging, and chronic inflammation also contribute significantly to these risks (Riddler et al., 2003).

Osteoporosis

Reduced bone mineral density is more common in PLWH than in the general population. Chronic inflammation, vitamin D deficiency, ART toxicity (especially tenofovir disoproxil fumarate), and low body weight contribute to this problem. Osteoporosis increases the risk of fractures and long-term disability (Brown & Qaqish, 2006).

The Role of Artificial Intelligence in HIV/AIDS Management

Artificial intelligence is transforming modern healthcare through the power of data-driven decision-making and automation. In HIV/AIDS care, AI tools are enhancing clinical decision-making, optimizing resource allocation, and tailoring interventions based on individual patient profiles.

AI in HIV Treatment

AI applications in HIV treatment include predictive analytics and personalized regimen selection. Machine learning algorithms analyze electronic health records, behavioral data, and socio-demographic profiles to identify patients at risk for non-adherence to ART. This enables providers to intervene early with support strategies. For instance, Esteva et al. (2019) demonstrated the ability of ML models to predict ART adherence with high accuracy.

Additionally, AI can assist clinicians in selecting the most effective ART regimens by integrating data on genetic markers, viral load trends, and historical drug responses. Such precision medicine approaches reduce the risk of adverse effects, prevent resistance, and improve overall treatment outcomes (Wang et al., 2018).

AI in HIV Prevention

Prevention remains a cornerstone in the effort to control HIV transmission. AI is being used to identify populations at heightened risk and guide the distribution of interventions like pre-exposure prophylaxis (PrEP). Predictive modeling can pinpoint

geographic regions and social networks most vulnerable to outbreaks. Schneider et al. (2020) used these models to forecast HIV incidence in U.S. counties, enabling more efficient public health responses.

Moreover, AI tools can support PrEP campaigns by identifying individuals who may benefit based on behavioral patterns and environmental data. This level of targeting ensures resources are allocated effectively, particularly in high-risk and underserved communities (Panch et al., 2019).

AI in HIV Education

AI-powered educational tools are bridging knowledge gaps in both patients and healthcare providers. Chatbots and virtual assistants such as Florence offer on-demand information on HIV management, prevention strategies, and medication adherence. These tools are especially beneficial for populations with limited access to in-person health services (Rielly, 2020).

In clinical settings, AI can personalize educational content based on user behavior, language proficiency, and comprehension levels. For healthcare professionals, AI platforms can provide real-time updates on clinical guidelines, drug interactions, and comorbidity management (Jiang et al., 2017).

Conclusion

While ART has significantly improved outcomes for people living with HIV, comorbidities such as cardiovascular disease, cancers, neurocognitive impairments, metabolic disorders, and osteoporosis continue to present complex challenges. These issues necessitate a multidisciplinary approach and innovative solutions.

Artificial intelligence holds great promise in transforming the landscape of HIV/AIDS care. Its ability to harness and interpret vast datasets enables more accurate predictions, targeted interventions, and customized education. Continued investment in AI technology—paired with equitable access and robust ethical frameworks—can enhance the quality of care for PLWH globally, particularly in resource-constrained environments.

References

1. Brown, T. T., & Qaqish, R. B. (2006). Antiretroviral therapy and the prevalence of

- osteopenia and osteoporosis: A meta-analytic review. *AIDS*, 20(17):2165–2174.
2. Esteva, A., Robicquet, A., Ramsundar, B., et al. (2019). A guide to deep learning in healthcare. *Nature Medicine*, 25:24–29.
 3. Heaton, R. K., Clifford, D. B., Franklin, D. R., et al. (2010). HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology*, 75(23):2087–2096.
 4. Jiang, F., Jiang, Y., Zhi, H., et al. (2017). Artificial intelligence in healthcare: Past, present and future. *Stroke and Vascular Neurology*, 2(4):230–243.
 5. Panch, T., Mattie, H., & Atun, R. (2019). Artificial intelligence and algorithmic bias: Implications for health systems. *Journal of Global Health*, 9(2):010318.
 6. Riddler, S. A., Haubrich, R., DiRienzo, A. G., et al. (2003). Class-sparing regimens for initial treatment of HIV-1 infection. *The New England Journal of Medicine*, 348(3):209–221.
 7. Rielly, A. (2020). Florence: The AI chatbot revolutionizing patient education. *Digital Health Journal*, 6(1):15–21.
 8. Schneider, J. A., Zhou, A. N., & Laumann, E. O. (2020). A predictive risk model for HIV outbreaks in U.S. counties. *PLoS ONE*, 15(3):e0226785.
 9. Shiels, M. S., Pfeiffer, R. M., & Gail, M. H. (2011). Cancer burden in the HIV-infected population in the United States. *Journal of the National Cancer Institute*, 103(9):753–762.
 10. Triant, V. A. (2013). Cardiovascular disease and HIV infection. *Current HIV/AIDS Reports*, 10(3):199–206.
 11. Wang, S., Summers, R. M., & Barua, S. (2018). Machine learning in medicine: AI solutions for HIV care. *Journal of the American Medical Association*, 320(22):2347–2348.

Cite this article: Uchechukwu P. Ahanonu, Feyisara L. Abati. (2025). Comorbidities of HIV/AIDS and the Role of Artificial Intelligence in Treatment, Prevention, and Education, *Journal of BioMed Research and Reports*, BioRes Scientia Publishers. 8(3):1-3. DOI: 10.59657/2837-4681.brs.25.189

Copyright: © 2025 Uchechukwu Promise Ahanonu, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Article History: Received: July 01, 2025 | Accepted: July 14, 2025 | Published: July 21, 2025